195 Longitudinal tau PET and atrophy 14. Visser D, Wolters EE, Verfaillie SC, Coomans EM, Timmers T, Tuncel H, et al. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease. European journal of nuclear medicine and molecular imaging. 2020;47:3165-75. 15. Heeman F, Visser D, Yaqub M, Verfaillie S, Timmers T, Pijnenburg YA, et al. Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals. Journal of Cerebral Blood Flow & Metabolism. 2022:0271678X221135270. 16. Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E, Ceyssens S, Van Broeckhoven C, et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: Validation against 15O-H2O PET. Alzheimer’s & Dementia. 2019;15:1172-82. 17. Peretti DE, Vállez García D, Reesink FE, Doorduin J, de Jong BM, De Deyn PP, et al. Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease. EJNMMI research. 2019;9:1-9. 18. Peretti DE, Vállez García D, Reesink FE, van der Goot T, De Deyn PP, de Jong BM, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies. PloS one. 2019;14:e0211000. 19. Korte N, Nortley R, Attwell D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer’s disease. Acta Neuropathologica. 2020;140:793-810. 20. Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nature neuroscience. 2018;21:1318-31. 21. Ahmadi K, Pereira JB, Berron D, Vogel J, Ingala S, Strandberg OT, et al. Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease. Journal of Cerebral Blood Flow & Metabolism. 2022:0271678X221141139. 22. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14:535-62. 23. Ebenau JL, Visser D, Verfaillie SC, Timmers T, van Leeuwenstijn MS, Kate Mt, et al. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals. European Journal of Nuclear Medicine and Molecular Imaging. 2022:1-13. 24. Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, et al. Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? Journal of Nuclear Medicine. 2008;49:1465-71. 25. Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. Journal of Alzheimer’s Disease. 2018;62:1091-111. 26. Jessen F, Amariglio RE, Van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & dementia. 2014;10:844-52. 27. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Focus. 2013;11:96-106. 7
RkJQdWJsaXNoZXIy MjY0ODMw